However, given the potential regulatory role that the MIF-CD74 axis may play in innate immune system responses, and the clinical promise of immunotherapy in management of TNBCs, it is essential to clarify some of the conflicting reports on associations between CD74 expression and clinico-pathologic parameters in BC, particularly in TNBCs. This evidence concerns the gene CD74 and breast cancer.